Medicinal Plant Research 2025, Vol.15, No.5, 224-232 http://hortherbpublisher.com/index.php/mpr 231 Gong F., Qu R., Li Y., Lv Y., and Dai J., 2022, Astragalus mongholicus: a review of its anti-fibrosis properties, Front. Pharmacol., 13: 976561. https://doi.org/10.3389/fphar.2022.976561 Law S., Lo C., Han J., Leung A., and Xu C., 2020, Traditional Chinese herb, Astragalus: possible for treatment and prevention of COVID-19?, Herba Polon., 66: 79-84. https://doi.org/10.2478/hepo-2020-0023 Nguyen M., Nguyen V., Yang S., Min B., and Kim J., 2024, Astraoleanosides E-P, oleanane-type triterpenoid saponins from the aerial parts of Astragalus membranaceus Bunge and their β-glucuronidase inhibitory activity, Bioorg. Chem., 145: 107230. https://doi.org/10.1016/j.bioorg.2024.107230 Pei C., Wang F., Huang D., Shi S., Wang X., Wang Y., Li S., Wu Y., and Wang Z., 2021, Astragaloside IV protects from PM2.5-induced lung injury by regulating autophagy via inhibition of PI3K/Akt/mTOR signaling in vivo and in vitro, J. Inflamm. Res., 14: 4707-4721. https://doi.org/10.2147/JIR.S312167 Selker H., Eichler H., Stockbridge N., Mcelwee N., Dere W., Cohen T., Erban J., Seyfert-Margolis V., Honig P., Kaitin K., Oye K., and D’Agostino R., 2019, Efficacy and effectiveness too trials: clinical trial designs to generate evidence on efficacy and on effectiveness in wide practice, Clin. Pharmacol. Ther., 105: 857-866. https://doi.org/10.1002/cpt.1347 Shen C., Gu Y., Wang S., and Yu L., 2019, Astragaloside IV, the major bioactive component of Astragalus membranaceus (Fisch.) Radix, attenuates airway inflammation by modulating Th2 cytokines, STAT6 and ROR-γτ transcription factors in an asthmatic mouse model, J. Immunol. https://doi.org/10.4049/jimmunol.202.supp.183.6 Su G., Chen X., Liu Z., Yang L., Zhang L., Lundborg S., Wen Z., Guo X., Qin X., Liang J., and Liu X., 2016, Oral Astragalus (Huang qi) for preventing frequent episodes of acute respiratory tract infection in children, Cochrane Database Syst. Rev., 12: CD011958. https://doi.org/10.1002/14651858.CD011958.pub2 Sun C., Liu H., Chi B., Han J., Koga Y., Afshar K., and Liu X., 2024, Improvement of idiopathic pulmonary fibrosis through a combination of Astragalus radix and Angelica sinensis radix via mammalian target of rapamycin signaling pathway-induced autophagy in rat, J. Thorac. Dis., 16: 1397-1411. https://doi.org/10.21037/jtd-24-28 Tan J., Yi J., Cao X., Wang F., Xie S., and Dai A., 2023, Untapping the potential of Astragaloside IV in the battle against respiratory diseases, Drug Des. Dev. Ther., 17: 1963-1978. https://doi.org/10.2147/DDDT.S416091 Wang S., Wang Q., Jiao L., Huang Y., Garfield D., Zhang J., and Xu L., 2016, Astragalus-containing Traditional Chinese Medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis, Curr. Oncol., 23(3): e188-e195. https://doi.org/10.3747/co.23.2920 Wang W., Liu Q., and Jing W., 2019, Astragalus membranaceus improves therapeutic efficacy of asthmatic children by regulating the balance of Treg/Th17 cells, Chin. J. Nat. Med., 17(4): 252-263. https://doi.org/10.1016/S1875-5364(19)30029-9 Wang X., Wang Y., Huang D., Shi S., Pei C., Wu Y., Shen Z., Wang F., and Wang Z., 2022, Astragaloside IV regulates the ferroptosis signaling pathway via the Nrf2/SLC7A11/GPX4 axis to inhibit PM2.5-mediated lung injury in mice, Int. Immunopharmacol., 112: 109186. https://doi.org/10.1016/j.intimp.2022.109186 Wei Y., Qi M., Liu C., and Li L., 2023, Astragalus polysaccharide attenuates bleomycin-induced pulmonary fibrosis by inhibiting TLR4/NF-κB signaling pathway and regulating gut microbiota, Eur. J. Pharmacol., 175594. https://doi.org/10.1016/j.ejphar.2023.175594 Wu Y., Xiao W., Pei C., Wang M., Wang X., Huang D., Wang F., and Wang Z., 2020, Astragaloside IV alleviates PM2.5-induced lung injury in rats by modulating TLR4/MyD88/NF-κB signalling pathway, Int. Immunopharmacol., 91: 107290. https://doi.org/10.1016/j.intimp.2020.107290 Yang X., and Wang F., 2019, The effect of astragaloside IV on JAK2-STAT6 signalling pathway in mouse model of ovalbumin-induced asthma, J. Anim. Physiol. Anim. Nutr., 103(4): 1285-1293. https://doi.org/10.1111/jpn.13114 Ying Y., Sun C., Zhang S., Chen B., Yu J., Liu F., Wen J., Hou J., Han S., Yan J., Yang Z., and Xiong L., 2021, Induction of autophagy via the TLR4/NF-κB signaling pathway by astragaloside IV contributes to the amelioration of inflammation in RAW264.7 cells, Biomed. Pharmacother., 137: 111271. https://doi.org/10.1016/j.biopha.2021.111271 Yu J., Wen J., Ying Y., Yin W., Zhang S., Pang W., Wang C., Bian Y., Yuan J., Yan J., and Yang Z., 2022, Astragaloside triggers autophagy: Implication of a potential therapeutic strategy for pulmonary fibrosis, Biomed. Pharmacother., 154: 113603. https://doi.org/10.1016/j.biopha.2022.113603 Yuan B., 2021, Towards a clinical efficacy evaluation system adapted for personalized medicine, Pharmacogenomics Pers. Med., 14: 487-496. https://doi.org/10.2147/PGPM.S304420 Yuan F., Yang Y., Liu L., Zhou P., Zhu Y., Chai Y., Chen K., Tang W., Huang Q., and Zhang C., 2023, Research progress on the mechanism of astragaloside IV in the treatment of asthma, Heliyon, 9: e22149. https://doi.org/10.1016/j.heliyon.2023.e22149
RkJQdWJsaXNoZXIy MjQ4ODYzNA==